Pathologic choroidal neovascular endothelium (CNV endothelium)

Pathologic choroidal neovascular endothelium refers to the abnormal layer of endothelial cells that form new, leaky blood vessels originating from the choroid and extending into the subretinal space (StatPearls, 2023). This process, known as choroidal neovascularization (CNV), is a hallmark of neovascular age-related macular degeneration (nAMD) and is the primary cause of rapid vision loss in these patients (NIH/NEI, 2023). These endothelial cells are characterized by the overexpression of specific molecular markers, most notably vascular endothelial growth factor receptors (VEGFRs) and integrins such as alpha-v beta-3, which are absent or minimally expressed in mature, quiescent vessels (Nature Reviews Drug Discovery, 2017). Pharmacological intervention primarily targets these cells by inhibiting the VEGF signaling pathway, which is the main driver of their proliferation and increased vascular permeability (PubMed, PMID: 28814835). Drugs such as ranibizumab, aflibercept, and brolucizumab bind to VEGF ligands to prevent their interaction with receptors on the pathologic endothelium, leading to vessel stabilization and fluid reduction (FDA, 2023). While highly effective, these therapies require frequent intravitreal injections and carry risks such as endophthalmitis or intraocular pressure elevation (Mayo Clinic, 2023). Research into targeted delivery systems, such as RGD-peptide-modified nanoparticles, aims to specifically home in on this pathologic endothelium to improve efficacy and reduce off-target effects (Journal of Controlled Release, 2021).

Other names

Choroidal neovascularization endotheliumNeovascular endothelial cellsAngiogenic choroidal endotheliumPathological ocular endotheliumCNV membrane endothelium

Inhibition of vascular endothelial growth factor (VEGF) signaling to suppress angiogenesis and reduce vascular permeability in the choroidal vasculature.